| Species : |
Human |
| Source : |
Mammalian Cells |
| Tag : |
His |
| Protein Length : |
2-714 a.a. |
| Description : |
AGGF1, wasidentified by its association with KlippelTrenaunay syndrome (KTS), acongenital vascular morphogenesis disorder. Two genetic alterations found inKTS lead to aberrant expression or function of AGGF1: a chromosomal translocationthat falls within the AGGF1 promoter and a glutamate to lysine point mutationat position 133. The human AGGF1 cDNA encodes a 714 amino acid (aa) precursorwith a coiled coil domain, an FHA domain, a G-patch domain, and an OCREdomain. FHA domains bind phosphorylated threonine and tyrosine residues. |
| Form : |
Lyophilized from a0.2 μm filtered solution in PBS. |
| N-terminalSequence : |
His |
| Molecular Weight : |
82.0 kDa |
| Activity : |
Measured by itsbinding ability in a functional ELISA. Immobilized rh AGGF1 at 1 μg/mL (100μL/well) can bind rhTWEAK with a linear range of 0.8-50 ng/mL. |
| Endotoxin Level : |
< 1.0EU per 1 μg of the protein by the LAL method. |
| SDS-PAGE : |
120-140 kDa,reducing conditions. |
| Purity : |
> 95%,by SDS-PAGE under reducing conditions and visualized by silver stain. |
| Reconstitution : |
100μg/mL in sterile PBS. |
| Storage : |
Use a manualdefrost freezer and avoid repeated freeze-thaw cycles. 12 months from date ofreceipt, -20 to -70°C as supplied. 1 month, 2 to 8°C under sterile conditionsafter reconstitution. 3 months, -20 to -70°C under sterile conditions after reconstitution. |